Release date: September 9, 2025

Expiration date: September 9, 2026

Program Code: 25-HF-33-W

TARGET AUDIENCE: Healthcare professionals, including physicians, advanced practice providers, nurses, and pharmacists who treat patients with substance use disorders.

LEARNING OBJECTIVES: At the conclusion of this activity, learners should be better able to: 1) Recognize best prescribing practices for medications for opioid use disorder (MOUD) during the perioperative period. 2) Identify with your team optimal post-operative pain management for patients receiving MOUD.

ACCREDITATION STATEMENT:

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and MidAtlantic AIDS Education and Training Center of the Health Federation of Philadelphia American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurse Practitioners and Nurses

American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours. 

Pharmacy

American Academy of CME, Inc., designates this educational activity for 1.0 ACPE contact hours. UAN: JA4008191-9999-25-044-

L01-P, Knowledge.

Other HCPs

Other members of the care team will receive a certificate of participation.

DISCLOSURES

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and any relevant financial relationships listed for these individuals have been mitigated.

Faculty 

Dennis Goodstein, PharmD, BCPS: No relevant financial relationships with ineligible companies to disclose.

Planning Committee

Catherine Abrams, MPH, Desiree Surplus, PharmD, AAHIVP, and John JD Juchniewicz, MCIS, CHCP, FACEHP, Caroline Olechna, MPH: No relevant financial relationships to disclose.

Daniel Texeira da Silva, MD, MSHP, discloses he is a shareholder of Atai life science, Cybin Inc, Compass pathways

This activity will not review off-label uses of approved agents. 

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Health Federation of Philadelphia. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

INSTRUCTIONS ON HOW TO RECEIVE CREDIT:

There are no fees to participate in the activity. To receive CME/CNE/CPE credit for your participation, please complete the program evaluation. Your certificate will be emailed to you in approximately 4 weeks.

For questions or comments about this activity, contact: surge@healthfederation.org